Improving the Chemo-Immunotherapy Response in Bladder Cancer
Researchers found that because the novel drug combination of an anti-inflammatory medication like celecoxib, chemotherapy and immunotherapy potentially can increase the chemoimmunotherapy response in patients with muscle-invasive bladder cancer. Each year, more than 83,000 new U.S. cases of bladder cancer are diagnosed in men and women. About one quarter of those newly diagnosed have the muscle-invasive type.
Source: genengnews.com
